Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b/2, Subprotocol of DAY101 in Combination With Pimasertib for Patients With Recurrent, Progressive, or Refractory Solid Tumors and MAPK Pathway Aberrations

NCT07121829 is registered in ClinicalTrials.gov with Day One Biopharmaceuticals, Inc. as lead sponsor.

NCT NCT07121829
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07121829 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b/2, Subprotocol of DAY101 in Combination With Pimasertib for Patients With Recurrent, Progressive, or Refractory Solid Tumors and MAPK Pathway Aberrations
Lead sponsor
Day One Biopharmaceuticals, Inc.
Phase
Phase 1
Overall status
Terminated
Start date
May 2, 2022
Completion date
December 18, 2024
Enrollment
44 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer, map kinase family gene mutation, mek mutation, melanoma, non small cell lung cancer, pancreatic cancer, pilocytic astrocytoma, raf mutation, ras mutation, solid tumor